Hemab
Business Services · Denmark · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Nordre Fasanvej 215, Frederiksberg, Regi...Website
www.hemab.comRevenue
-Industry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
2
1
1
About Hemab
Hemab is a multiple clinical-asset biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Based in Cambridge, MA, and Copenhagen, Denmark, Hemab is progressing a pipeline of innovative therapeutic solutions, leveraging a variety of cutting-edge technologies and approaches to transform the treatment paradigm for patients with high unmet need.Explore more
Hemab Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Hemab your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Hemab recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Hemab has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Hemab
Website visits: Recent activity has been detected on your website
Click to see if Hemab had a recent Job posting/layoffs
Product Launch: Get notified when Hemab launches new products
Hemab, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Hemab is spiking on competitors!
Funding: Get notified immidiatlly once Hemab has new funding data
Recommended Actions
Find VP level buyers at Hemab
Find 3 more new buyers
Compare Similar Companies to Hemab
Compare insights from companies similar to Hemab, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Hemab is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Hemab is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Hemab.
Hemab financials insights
Gather financial insights about Hemab, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$55M
2023
Series B
$135M
2025
Series C
$157M
2026
IPO
$301.5M
Hemab Tech Stack
A closer look at the technologies used by Hemab
See more technologies
Most Recent Scoops
Open Position
Initial Public Offering (IPO)
IPO, Finance
Funding
IPO, Funding
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Hemab News & Media
Hemab Therapeutics Reports First Quarter 2026 Financial Results
Completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on NasdaqHemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 04, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced the closing of its initial public offering of 19,262,500 shares of its common stock at a public offering price of $18.00 per share, including 2,512,500 additional shares of common stock issued upon theHemab Therapeutics Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced the pricing of its initial public offering of 16,750,000 shares of its common stock at a public offering price of $18.00 per share. In addition, Hemab has granted the underwriters a 30-day option toSeaport, Hemab chart courses for $180M IPOs to fund depression, clotting candidates
Both Seaport Therapeutics and Hemab Therapeutics are hoping to bring in around $180 million each from their public listings this week, in the latest sign that biotech IPOs are regaining their momen | Both Seaport and Hemab are hoping to bring in around $180 million each from their public listings this week, in the latest sign that biotech IPOs are regaining their momentum.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Hemab
Sign Up For FreeTo access detailed company insights
Hemab is a multiple clinical-asset biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Based in Cambridge, MA, and Copenhagen, Denmark, Hemab is progressing a pipeline of innovative therapeutic solutions, leveraging a variety of cutting-edge technologies and approaches to tran... Read More
